Albany, NY -- (ReleaseWire) -- 06/19/2014 -- Transparency Market Research, a leading business intelligence provider of market research reports has published a new report based on “HIV Market – Global and China Forecast, Share, Size, Growth and Industry Analysis (2010 - 2017)”. According to the report, the global market for HIV therapeutics and diagnostics is expected to grow to $18.2 billion in 2013, and reach a value of $19.6 billion in 2017, along with a compound annual growth rate (CAGR) of 1.5% in the given forecast period.
Buy This Report @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=113
Transparency Market Research’s report covers analysis of the unmet needs, barriers, growth drivers, and major key players involved in this market.
The report provides insights into the Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome) HIV/AIDS therapeutics market of the defined forecast period of 2010 – 2017, with comprehensive analysis of the major marketed products, as well as insights into the HIV/AIDS therapeutics R&D industry. It also contains the global scenario of HIV therapeutic market discussing detailed overview, market figures, industry growth rate, industry capacity, industry structure, historical data and forecasts of the overall HIV market.
HIV virus was discovered in 1981 and since then, it has killed more than 35 million people in the world. Human immuno deficiency virus is a type of disorder that causes continuous failure of immune systems in the body which ultimately leads to death. HIV/AIDS infections are primarily caused during transfer of blood, vaginal fluid, unsafe sex, infected needles, and due to many other reasons. The discovery of HIV virus that leads to AIDS dates back to more than thirty decades. However, with passing years, the advancements in the field of pharmacy and medicine have led us to new drugs that help in improving the quality of life for HIV patients. This industry consists of various therapies and medicines that are meant to address the unmet needs of drug resistance and toxicity involved with HIV. There are more than 30 drugs available in the market which has been approved by the FDA for treating HIV infection. Nevertheless, it is understood that the existing therapies are not permanent curatives, but must be taken for a lifetime by the patients who are diagnosed with HIV.
According to worldwide research analysts, the current situation of the HIV market is strong, displaying a high degree of novelty and diversity in drugs and medical treatments. Currently, the market is deemed to mature and expand with numerous treatment and test procedures, which prove to be rather effective in suppressing the HIV disease, and increase the patients’ life expectancy.
The rate of HIV infections and its subsequent reduction in the number of deaths caused due to AIDS have been witnessed on a declining note at a fairly positive rate across the globe. The major cause for such tremendous oppression in the infection rates has been due to the improved access to antiretroviral drugs and therapy in the recent years. It is also primarily driven by the increase in the use of single dose multi-class combination drugs like Atripla, Complera and the recent launch of Stribild (previously known as Quad).
This report analyzes treatment usage patterns, HIV market forecasts, drug types available, and various indications related to HIV. The countries covered in the global study of HIV market include the US, Germany, France, Spain, Italy, the UK, Japan, and Canada. However, majority of the HIV infected population lives in sub Saharan Africa.
Browse Full Report @ http://www.transparencymarketresearch.com/hiv-market.html